Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase.
about
Ranpirnase Interferes with NF-κB Pathway and MMP9 Activity, Inhibiting Malignant Mesothelioma Cell Invasiveness and Xenograft GrowthRNase A ribonucleases and host defense: an evolving storyRibonucleases as novel chemotherapeutics : the ranpirnase exampleRegulation of cell death by transfer RNAOnconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytesTNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesisArginine residues are more effective than lysine residues in eliciting the cellular uptake of onconase.Identification of genes differentially expressed during larval molting and metamorphosis of Helicoverpa armigera.Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent.Site-specific RNase A activity was dramatically reduced in serum from multiple types of cancer patients.A human ribonuclease induces apoptosis associated with p21WAF1/CIP1 induction and JNK inactivation.Antitumor activity of ribonuclease multimers created by site-specific covalent tethering.tRNA and cytochrome c in cell death and beyond.Towards tricking a pathogen's protease into fighting infection: the 3D structure of a stable circularly permuted onconase variant cleavedby HIV-1 proteaseMicroRNA drop in the bloodstream and microRNA boost in the tumour caused by treatment with ribonuclease A leads to an attenuation of tumour malignancy.Role of Oxidative RNA Damage in Chronic-Degenerative Diseases.Tumoricidal Activity of RNase A and DNase I.Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma.tRNA cleavage is a conserved response to oxidative stress in eukaryotes.Cytostatic and cytotoxic properties of Amphinase: a novel cytotoxic ribonuclease from Rana pipiens oocytes.Ribonuclease binase inhibits primary tumor growth and metastases via apoptosis induction in tumor cells.Current concepts in malignant pleural mesothelioma.Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies.Ranpirnase and its potential for the treatment of unresectable malignant mesotheliomaActivating transcription factor 3 is crucial for antitumor activity and to strengthen the antiviral properties of Onconase.Apoptotic regulation and tRNA.Antibody-enzyme fusion proteins for cancer therapy.Leczyme: a new candidate drug for cancer therapy.The decalog of long non-coding RNA involvement in cancer diagnosis and monitoring.Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines.Onconase cytotoxicity relies on the distribution of its positive charge.Contribution of the C30/C75 disulfide bond to the biological properties of onconase.tRNA binds to cytochrome c and inhibits caspase activation.Remarkable enhancement of cytotoxicity of onconase and cepharanthine when used in combination on various tumor cell lines.The growing impact of lyophilized cell-free protein expression systems.Contribution of electrostatics to the binding of pancreatic-type ribonucleases to membranes.Sialic acid-binding lectin (leczyme) induces caspase-dependent apoptosis-mediated mitochondrial perturbation in Jurkat cells.The systemic tumor response to RNase A treatment affects the expression of genes involved in maintaining cell malignancy.Evolution and function of leukocyte RNase A ribonucleases of the avian species, Gallus gallus.
P2860
Q24612464-353CFF56-2F99-43FD-81EB-2E4FFEDF0F4AQ24650072-F8C7DECA-2C16-4BFD-A158-A8CC11FBB477Q24650138-098D393E-9782-488B-ACA4-1B2A0C46D574Q27003645-0E4B7E57-FE4F-42F8-AFCC-250AAA6D4779Q28289485-7AC1BE08-3857-44FA-80DB-0EA3A5054E23Q28389414-BE9C82A0-6FAB-4ECD-A6AA-F85FDFF5DE5CQ30407943-9666D37E-45AF-47C9-A95D-49F90E2A2120Q33288657-9AD5223C-E9AE-410A-80E7-FEDEAC37D8FBQ33529876-744AA27B-164C-4363-A260-305F4E15527AQ33578043-48770BB9-7E0E-452F-BF3B-1307CC08068EQ33790446-14CD64E5-5392-41C5-8B08-2452D2B31A57Q34130092-25C4F839-8D42-471B-B1C0-486F1D9A817FQ34318143-393AB3F5-0B2E-42F5-B17A-EC2135890339Q34563323-5771CF08-667E-4A9D-83A1-4B80FDD91DC1Q35080416-DF449266-8DD6-49B9-BD60-C867D6EE8F22Q35675884-3F9729EC-52CC-4461-AAFD-3FD5DD01797CQ35944314-EDC51859-5BBE-4630-AC67-2295E8681A17Q36425940-BA6605B6-4E81-48E1-80CD-C49BD2672C2CQ36909679-C81D72A4-C030-4654-8BE3-C4283D575A69Q36982671-C93B4254-B00A-47FB-876A-426D917A966FQ37079775-A34E2C97-F7DF-48E5-B829-CC4612A8870FQ37086026-E73611F9-A65B-4119-80AB-32AB5DD57762Q37179384-2C4004BD-BF7D-4B2B-904A-BC6A23725EAEQ37307815-06CB622E-1081-4815-A2E0-12989FBA0A3EQ37706969-C4CA015D-54F1-4E96-959F-04C0A4C8337FQ37813031-A8992ECB-E0F5-4511-86DC-F30AD9F159FDQ37842324-63A20839-D76D-4C0D-AE21-7CA6348D2890Q38215190-6EA7A7A5-0E5B-4A75-BD5F-43B02F5B2DC8Q38239897-977067CA-51BE-4D64-AF3A-884D01D11B88Q38949072-66DFE414-6849-4A81-8839-DB2240C082CDQ39599234-DBF33F53-2B6F-47C3-A33C-16B87942C9FEQ39838747-4A420A97-638F-4C67-8860-82ADF406BE28Q39922181-093EA665-332B-4FAC-A19E-2A7FADBEE506Q39941332-BED0A833-A75D-45F3-939A-DBB3FF9D7422Q39987355-4F7EE903-88BF-43C2-848F-53BB3C99CD51Q42536890-ADCE88BB-5C1A-49D4-BBBB-055B1FD35327Q42869373-B54D7B9C-D530-40EF-84C3-5508E91A6794Q42913880-846519BA-6D4C-4A33-AFBE-6D99A31D889EQ43154335-029235FA-215E-4737-A6BB-C202B82145E8Q48086448-E7334DB1-2B73-48F6-8E51-A2C8FE7F8964
P2860
Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Ribonucleases as a novel pro-a ...... clinical data for ranpirnase.
@ast
Ribonucleases as a novel pro-a ...... clinical data for ranpirnase.
@en
type
label
Ribonucleases as a novel pro-a ...... clinical data for ranpirnase.
@ast
Ribonucleases as a novel pro-a ...... clinical data for ranpirnase.
@en
prefLabel
Ribonucleases as a novel pro-a ...... clinical data for ranpirnase.
@ast
Ribonucleases as a novel pro-a ...... clinical data for ranpirnase.
@en
P2093
P2860
P1433
P1476
Ribonucleases as a novel pro-a ...... clinical data for ranpirnase.
@en
P2093
David Sidransky
Howard Goldsweig
John Costanzi
P2860
P304
P356
10.1080/07357900500283143
P577
2005-01-01T00:00:00Z